Mössner, Rotraut

[["dc.bibliographiccitation.firstpage","989"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","The Journal of Dermatology"],["dc.bibliographiccitation.lastpage","997"],["dc.bibliographiccitation.volume","47"],["dc.contributor.author","Kromer, Christian"],["dc.contributor.author","Loewe, Emilia"],["dc.contributor.author","Schaarschmidt, Marthe‐Lisa"],["dc.contributor.author","Pinter, Andreas"],["dc.contributor.author","Gerdes, Sascha"],["dc.contributor.author","Celis, Daniel"],["dc.contributor.author","Poortinga, Sietske"],["dc.contributor.author","Wilsmann‐Theis, Dagmar"],["dc.contributor.author","Mössner, Rotraut"],["dc.date.accessioned","2021-04-14T08:24:11Z"],["dc.date.available","2021-04-14T08:24:11Z"],["dc.date.issued","2020"],["dc.description.abstract","Abstract Acrodermatitis continua of Hallopeau (ACH) is a rare chronic inflammatory skin disease. Treatment is extremely challenging and mostly based on empirics as there is only scarce evidence from case reports and few small case series. In this retrospective study, patients with ACH treated at five university medical centers were analyzed according to patient and disease characteristics and treatment experience. We identified 39 patients with ACH with a mean age of 54.4 years at onset, of whom 22 (56.4%) were female. A total of 115 systemic treatment courses were analyzed with methotrexate as the most common therapy (27.0%). Overall, effectiveness of systemic treatments was low (excellent response rate: 14.8%). Among non‐biologics, excellent response was noted in 21.1% (4/19) of treatment courses with methotrexate, followed by acitretin (13.3%; 2/15). Among biologics, guselkumab (excellent response: 100%; 2/2), secukinumab (excellent response: 42.9%; 3/7) and adalimumab (excellent response: 20.0%; 2/10) were most efficacious. The median drug survival was 7.0 months and did not differ significantly between the subgroup of non‐biologic and biologic therapies. To our knowledge, this is the largest case series in ACH investigating patient characteristics and treatment outcomes. Based on our treatment experience, we suggest a treatment algorithm starting with acitretin or methotrexate as first‐line therapy, followed by biologics. Cyclosporin may be used for short‐term control. However, none of the applied systemic therapies yielded satisfying efficacy in our cohort. In patients with primary non‐response, switch of treatment should be evaluated timely on an individual basis, considering possible irreversible disease complications such as nail loss. More research with prospective design is needed to further evaluate traditional and also particularly newer antipsoriatic drugs in ACH."],["dc.identifier.doi","10.1111/1346-8138.15466"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81196"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1346-8138"],["dc.relation.issn","0385-2407"],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made."],["dc.title","Treatment of acrodermatitis continua of Hallopeau: A case series of 39 patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","6232S"],["dc.bibliographiccitation.issue","16"],["dc.bibliographiccitation.journal","Clinical Cancer Research"],["dc.bibliographiccitation.lastpage","6233S"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Mossner, Rotraut"],["dc.contributor.author","Schulz, U."],["dc.contributor.author","Kuger, U."],["dc.contributor.author","Middel, Peter"],["dc.contributor.author","Fuzesi, Laszlo"],["dc.contributor.author","Neumann, C."],["dc.contributor.author","Reich, Kristian"],["dc.date.accessioned","2018-11-07T10:34:17Z"],["dc.date.available","2018-11-07T10:34:17Z"],["dc.date.issued","2003"],["dc.identifier.isi","000187467300668"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/44829"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Assoc Cancer Research"],["dc.publisher.place","Philadelphia"],["dc.relation.conference","AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics"],["dc.relation.eventlocation","BOSTON, MASSACHUSETTS"],["dc.relation.issn","1078-0432"],["dc.title","Role of peroxisome proliferator-activated receptor (PPAR) gamma in the control of melanoma cell growth."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Experimental Dermatology"],["dc.bibliographiccitation.volume","15"],["dc.contributor.author","Mossner, Rotraut"],["dc.contributor.author","Anders, N."],["dc.contributor.author","Konig, I. R."],["dc.contributor.author","Kruger, Ullrich"],["dc.contributor.author","Schmidt, D."],["dc.contributor.author","Berking, Carola"],["dc.contributor.author","Ziegler, Andreas"],["dc.contributor.author","Brockmoeller, Juergen"],["dc.contributor.author","Volkenandt, Matthias"],["dc.contributor.author","Kaiser, R."],["dc.contributor.author","Westphal, G."],["dc.contributor.author","Reich, Kristian"],["dc.date.accessioned","2018-11-07T10:12:01Z"],["dc.date.available","2018-11-07T10:12:01Z"],["dc.date.issued","2006"],["dc.format.extent","198"],["dc.identifier.isi","000235370600041"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40158"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Blackwell Publishing"],["dc.publisher.place","Oxford"],["dc.relation.conference","33rd Annual Meeting of the Arbeitsgemeinschaft-Dermatologische-Forschung (ADF)"],["dc.relation.eventlocation","Aachen, GERMANY"],["dc.relation.issn","0906-6705"],["dc.title","Variations of the MC1R and the GSTM1 and T1 genes in cutaneous malignant melanoma"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","202"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Journal der Deutschen Dermatologischen Gesellschaft"],["dc.bibliographiccitation.lastpage","204"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Lockmann, Anike"],["dc.contributor.author","Seitz, Cornelia S."],["dc.contributor.author","Schön, Michael P."],["dc.contributor.author","Mößner, Rotraut"],["dc.date.accessioned","2020-12-10T18:27:17Z"],["dc.date.available","2020-12-10T18:27:17Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1111/ddg.13414"],["dc.identifier.issn","1610-0379"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/76296"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Creeping eruption and eosinophilic folliculitis: Atypical cutaneous larva migrans"],["dc.title.alternative","Correspondence"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","39"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Clinical & Experimental Immunology"],["dc.bibliographiccitation.lastpage","44"],["dc.bibliographiccitation.volume","142"],["dc.contributor.author","Hofstetter, Harald H."],["dc.contributor.author","Mossner, Rotraut"],["dc.contributor.author","Lesch, K. P."],["dc.contributor.author","Linker, Ralf Andreas"],["dc.contributor.author","Toyka, Klaus V."],["dc.contributor.author","Gold, Ralf"],["dc.date.accessioned","2018-11-07T10:55:12Z"],["dc.date.available","2018-11-07T10:55:12Z"],["dc.date.issued","2005"],["dc.description.abstract","Serotonin (5-hydroxytryptamine, 5-HT) is one of the most extensively studied neurotransmitters of the central nervous system. It also has been identified in constituents of the immune system. Therefore serotonin has been suggested to serve as a mediator of bidirectional interactions between the nervous system and the immune system. We investigated this interaction in experimental autoimmune encephalomyelitis (EAE), a well-defined animal model of autoimmune disease of the central nervous system (CNS) mimicking features of the human disease multiple sclerosis. EAE was induced by immunization with the autoantigens myelin basic protein (MBP) or the immunodominant peptide of myelin oligodendrocyte glycoprotein (MOG) spanning amino acids 35-55 (MOGp 35-55). We studied EAE in knockout (KO) mice lacking the 5-HT transporter (5-HTT) on a C57.BL/6 background, in comparison with wild-type C57.BL/6 animals. After immunization with MOGp 35-55, or with rat MBP, the disease courses of the 5-HTT knockout mice were attenuated as compared to wildtype control mice. This difference was more pronounced in female animals. To dissect potential immune mechanisms underlying this phenomenon, histological studies of the CNS and cytokine measurements in mononuclear cells from the spleens of 5-HTT KO mice and wild-type controls were performed. We found a reduction of the inflammatory infiltrate in the CNS and of the neuroantigen-specific production of IFN-gamma in splenocytes, again accompanied by a gender difference. These findings suggest a potential role of extracellular 5-HT homeostasis in the fine-tuning of neuroantigen-specific immune responses."],["dc.identifier.doi","10.1111/j.1365-2249.2005.02901.X"],["dc.identifier.isi","000231824900005"],["dc.identifier.pmid","16178854"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/49732"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Blackwell Publishing"],["dc.relation.issn","0009-9104"],["dc.title","Absence of reuptake of serotonin influences susceptibility to clinical autoimmune disease and neuroantigen-specific interferon-gamma production in mouse EAE"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Clinical Infectious Diseases"],["dc.bibliographiccitation.volume","62"],["dc.contributor.author","Moessner, Rotraut"],["dc.contributor.author","Diering, Nina"],["dc.contributor.author","Bader, Oliver"],["dc.contributor.author","Forkel, Susann"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Gross, Uwe"],["dc.contributor.author","Grimbacher, Bodo"],["dc.contributor.author","Schoen, Michael Peter"],["dc.contributor.author","Buhl, Timo"],["dc.date.accessioned","2018-11-07T10:16:10Z"],["dc.date.available","2018-11-07T10:16:10Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.1093/cid/ciw020"],["dc.identifier.isi","000374248700026"],["dc.identifier.pmid","26787170"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40985"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press Inc"],["dc.relation.issn","1537-6591"],["dc.relation.issn","1058-4838"],["dc.title","Ruxolitinib Induces Interleukin 17 and Ameliorates Chronic Mucocutaneous Candidiasis Caused by STAT1 Gain-of-Function Mutation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","753"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Journal der Deutschen Dermatologischen Gesellschaft"],["dc.bibliographiccitation.lastpage","771"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Reich, Kristian"],["dc.contributor.author","Augustin, Matthias"],["dc.contributor.author","Gerdes, Sascha"],["dc.contributor.author","Ghoreschi, Kamran"],["dc.contributor.author","Kokolakis, Georgios"],["dc.contributor.author","Mößner, Rotraut"],["dc.contributor.author","Mrowietz, Ulrich"],["dc.contributor.author","Navarini, Alexander A."],["dc.contributor.author","Pinter, Andreas"],["dc.contributor.author","Schäkel, Knut"],["dc.contributor.author","Wilsmann‐Theis, Dagmar"],["dc.date.accessioned","2022-07-01T07:35:12Z"],["dc.date.available","2022-07-01T07:35:12Z"],["dc.date.issued","2022"],["dc.identifier.doi","10.1111/ddg.14764"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112108"],["dc.language.iso","de"],["dc.notes.intern","DOI-Import GROB-581"],["dc.relation.eissn","1610-0387"],["dc.relation.issn","1610-0379"],["dc.rights.uri","http://creativecommons.org/licenses/by-nc-nd/4.0/"],["dc.title","Generalized pustular psoriasis: overview of the status quo and results of a panel discussion"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","576"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of Investigative Dermatology"],["dc.bibliographiccitation.lastpage","582"],["dc.bibliographiccitation.volume","119"],["dc.contributor.author","Mossner, Rotraut"],["dc.contributor.author","Schulz, U."],["dc.contributor.author","Kruger, Ullrich"],["dc.contributor.author","Middel, Peter"],["dc.contributor.author","Schinner, S."],["dc.contributor.author","Fuzesi, Laszlo"],["dc.contributor.author","Neumann, C."],["dc.contributor.author","Reich, Kristian"],["dc.date.accessioned","2018-11-07T10:06:19Z"],["dc.date.available","2018-11-07T10:06:19Z"],["dc.date.issued","2002"],["dc.description.abstract","Peroxisome proliferator-activated receptor gamma is a member of the nuclear receptor superfamily involved in adipocyte differentiation and glucose homeostasis. There is evidence that peroxisome proliferator-activated receptor gamma may also act as a tumor suppressor. Here, we demonstrate expression of peroxisome proliferator-activated receptor gamma in benign melanocytic naevi, different variants of primary cutaneous melanomas, and melanoma metastases. Peroxisome proliferator-activated receptor gamma protein and peroxisome proliferator-activated receptor gamma1 mRNA were also detected in human melanoma cell lines. The peroxisome proliferator-activated receptor gamma specific agonists 15-deoxy-Delta(12,14)-prostaglandin J(2), troglitazone, and rosiglitazone dose-dependently inhibited cell proliferation in four melanoma cell lines, whereas a specific agonist of peroxisome proliferator-activated receptor alpha had no such effect. At a concentration of 50 muM rosiglitazone, the most potent peroxisome proliferator-activated receptor gamma agonist tested suppressed cell growth by approximately 90%. Apoptosis could be induced in melanoma cell lines by incubation with tumor-necrosis-factor-related apoptosis-inducing ligand. In contrast, the growth inhibitory effect of peroxisome proliferator-activated receptor gamma activation was independent of apoptosis and seemed to occur primarily through induction of cell cycle arrest. Our data indicate that melanoma cell growth may be modulated through peroxisome proliferator-activated receptor gamma."],["dc.identifier.doi","10.1046/j.1523-1747.2002.01861.x"],["dc.identifier.isi","000177951400006"],["dc.identifier.pmid","12230498"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39070"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Blackwell Publishing Inc"],["dc.relation.issn","0022-202X"],["dc.title","Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","643"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Journal der Deutschen Dermatologischen Gesellschaft"],["dc.bibliographiccitation.lastpage","645"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Schmid, Emilia"],["dc.contributor.author","Mohr, Johannes"],["dc.contributor.author","Schön, Michael P."],["dc.contributor.author","Mössner, Rotraut"],["dc.date.accessioned","2021-06-01T10:47:13Z"],["dc.date.available","2021-06-01T10:47:13Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1111/ddg.13857"],["dc.identifier.eissn","1610-0387"],["dc.identifier.issn","1610-0379"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85525"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","1610-0387"],["dc.relation.issn","1610-0379"],["dc.title","Two cases of acrodermatitis continua suppurativa (Hallopeau's disease) treated with IL‐17A inhibitors"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2149"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Journal of Investigative Dermatology"],["dc.bibliographiccitation.lastpage","2158.e10"],["dc.bibliographiccitation.volume","142"],["dc.contributor.author","Haskamp, Stefan"],["dc.contributor.author","Frey, Benjamin"],["dc.contributor.author","Becker, Ina"],["dc.contributor.author","Schulz-Kuhnt, Anja"],["dc.contributor.author","Atreya, Imke"],["dc.contributor.author","Berking, Carola"],["dc.contributor.author","Pauli, David"],["dc.contributor.author","Ekici, Arif B."],["dc.contributor.author","Berges, Johannes"],["dc.contributor.author","Mößner, Rotraut"],["dc.contributor.author","Hüffmeier, Ulrike"],["dc.date.accessioned","2022-09-01T09:49:41Z"],["dc.date.available","2022-09-01T09:49:41Z"],["dc.date.issued","2022"],["dc.description.sponsorship"," http://dx.doi.org/10.13039/501100001659 Deutsche Forschungsgemeinschaft"],["dc.identifier.doi","10.1016/j.jid.2021.12.021"],["dc.identifier.pii","S0022202X21026397"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/113500"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-597"],["dc.relation.issn","0022-202X"],["dc.rights.uri","https://www.elsevier.com/tdm/userlicense/1.0/"],["dc.title","Transcriptomes of MPO-Deficient Patients with Generalized Pustular Psoriasis Reveals Expansion of CD4+ Cytotoxic T Cells and an Involvement of the Complement System"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]